絞り込み

17057

広告

Patterns of Sensitivity to a Panel of Drugs are highly Individualized for Undifferentiated/Unclassified Soft Tissue Sarcoma (USTS) in Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Models.

著者 Kawaguchi K , Igarashi K , Miyake K , Kiyuna T , Miyake M , Singh AS , Chmielowski B , Nelson SD , Russell TA , Dry SM , Li Y , Unno M , Singh SR , Eilber FC , Hoffman RM
J Drug Target.2018 Jul 19 ; ():1-25.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

Medical

Research Materials

Undifferentiated/unclassified soft tissue sarcoma (USTS) is a recalcitrant disease, therefore, precise individualized therapy is needed. Toward this goal, we previously established patient-derived orthotopic xenograft (PDOX) models of USTS in nude mice. Here, we determined the extent of uniqueness of drug response in a panel on USTS PDOX models from 5 different patients. We previously showed that 3 of the 5 patients were resistant to DOX despite DOX being first-line therapy. Two weeks after orthotopic tumor implantation, PDOX mouse models were randomized into five groups: untreated control, doxorubicin (DOX), gemcitabine/docetaxel (GEM/DOC), pazopanib (PAZ); temozolomide (TEM) and 3 PDOX cases completely resistant to DOX. TEM had high efficacy for 4 USTS PDOX models, including DOX-resistant cases. GEM/DOC and PAZ were effective in three USTS PDOX. One case was completely resistance to TEM. Two cases were completely resistant to PAZ. The results showed the drug sensitivity pattern for each USTS PDOX was highly individualized and that at least one effective drug could be found for each. The PDOX model could be effective in precise individualized drug sensitivity testing which is especially important for heterogeneous cancers such as USTS, and can give the patient a greater chance to be treated with an effective drug.
PMID: 30024282 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード